Neurotoxicity and side-effects of Highly Active Antiretroviral Therapy [HAART] on the central and peripheral nerve system

Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry

Volumn 8, Issue 2, 2009, Pages 192-201

  Husstedt, I W ^a   Reichelt, D ^a   Neuen Jakob, E ^b   Kastner F ^a   Von Einsiedel, R ^d   Vielhaber, B ^e   Arendt, G ^b   Evers, S ^a   Hahn, K ^c  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d Asklepios Clinic   (Germany)

^e Die Werkstatt   (Germany)

Author keywords

Central and peripheral nervous system; HAART; Interactions; Neurotoxicity

Indexed keywords

ABACAVIR; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIRETROVIRUS AGENT; CITALOPRAM; DELAVIRDINE; DIDANOSINE; DIHYDROERGOTAMINE; DULOXETINE; EFAVIRENZ; ERGOMETRINE; ETIRACETAM; GABAPENTIN; INDINAVIR; LAMIVUDINE; NEVIRAPINE; PARACETAMOL; PREGABALIN; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TRICYCLIC ANTIDEPRESSANT AGENT; TRIPTAN DERIVATIVE; UNINDEXED DRUG; VENLAFAXINE; ZALCITABINE; ZIDOVUDINE;

ABNORMAL DREAMING; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANXIETY; CARDIOMYOPATHY; CATATONIA; COGNITIVE DEFECT; CONCENTRATION LOSS; DEPRESSION; DISORIENTATION; DIZZINESS; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG COMPETITION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EXPOSURE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG PENETRATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPILEPSY; EVENING DOSAGE; FATIGUE; FATTY LIVER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LACTIC ACIDOSIS; LIPODYSTROPHY; LOW DRUG DOSE; MANIA; MEMORY DISORDER; MIGRAINE; MUSCLE CRAMP; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; NEUROPATHIC PAIN; NEUROPATHY; NEUROTOXICITY; NIGHTMARE; NONHUMAN; PANCREATITIS; PARESTHESIA; PATIENT COMPLIANCE; POSITIVE END EXPIRATORY PRESSURE; PRENATAL DRUG EXPOSURE; PSYCHOSIS; PSYCHOTHERAPY; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SLEEP APNEA SYNDROME; SLEEP DISORDER; SOMNOLENCE; SUICIDE ATTEMPT; SURVIVAL TIME; TERATOGENICITY; TREATMENT DURATION;

EID: 73449110895     PISSN: 18715230     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152309789152039     Document Type: Review

References (58)

1. Proctor, V.E.; Tesfa, A.; Tompkins, D.C. Barriers to adherence to highly active antiretroviral therapy as expressed by people living with HIV/AIDS. AIDS Patient Care STDS, 1999, 13, 535-544.
2. Husstedt, I.W.; Potthoff, A.; Neuen-Jakob, E.; Hahn, K.; Kästner, F.; Arendt, G.; Evers, S.; Behrens, G.; Stoehr, A.; Schmied, B.; Neumann, T.; Hartmann, M.; Schöfer, H.; Brockmeyer, N.H. Beitrag zur Deutsch-Österreichischen Therapieempfehlungen der HIVInfektion Erwachsener, Gruppe 4: Nebenwirkungen der Therapie., 2008. http//:www.daignet.de
3. Monforte, A.; Lepri, A.C.; Rezza, G. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy [HAART] regimen in a cohort of antiretroviral naive patients. AIDS 2000, 14, 499-507.
4. Hofstedde, H.J.M.; Burger, D.M.; Koopmans, P.P. Antiretroviral therapy in HIV patients: aspects of metabolic complications and mitochondria toxicity. Neth. J. Med., 2003, 61, 393-403.
5. Keilbaugh, S.A.; Prusoff, W.H.; Simpson, M.V. The PC12 cell as a model for studies of the mechanism of induction of peripheral neuropathy by anti-HIV-1 dideoxynucleoside. Biochem. Pharmacol., 1991, 42, 5-8.
6. Medina, D.J.; Tsai, C.H.; Hsiung, G.D.; Cheng, Y.C. Comparison and mitochondrial morphology, mitochondrial DNA content, and cell viability in cultured cells treated with three anti-human immunodeficiency virus dideoxynucleosides. Antimicrobial. Agents Chemother., 1994, 46, 1824-1828.
7. Johnson, A.A.; Ray, A.S.; Hanes, J.; Suo, Z.; Colacino, J.M.; Andersen, K.S.; Johnson, K.A. Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase. J. Biol. Chem., 2001, 276, 40847-40857.
8. Lee, H.; Hanes, J.; Johnson, K.A. Toxicity of nucleoside analogues used to treat AIDS and the selectivity of the mitochondrial DNA polymerase. Biochemistry, 2003, 42, 14711-14719.
9. Martin, A.M.; Hammond, E.; Nolan, D.; Pace, C.; Den Boer, M.; Taylor, L.; Moore, H.; Martinez, O.P.; Christiansen, F.T.; Mallal ,S. Accumulation of mitochondrial DNA mutations in human immunodeficiency virus-infected patients treated with nucleoside analogue reverse-transcriptase inhibitors. Am. J. Hum. Genet., 2003, 72, 549-560.
10. Lewis, W.; Kohler, J.J.; Hosseini, S.H.; Haase, C.P.; Copeland, W.C.; Bienstock, R.J.; Ludaway, T.; McNaught, J.; Russ, R.; Stuart, T.; Santoianni, R. Antiretroviral nucleosides, deoxynucleotide carrier and mitochondrial DNA: evidence supporting the DNA polγ- hypothesis. AIDS, 2006, 20, 675-684.
11. Poirier, M.C.; Divi, R.L.; Al Harthi, L. Long-term mitochondrial toxicity in HIV-uninfected infants born to HIV-infected mothers. J. Acquir. Immune Defic. Syndr., 2003, 33, 175-183.
12. Nolan, D.; Mallal, S. Complications associated with NRTI therapy: update on clinical features and possible pathogenic mechanisms. Antivir. Ther., 2004, 9, 849-863.
13. Deutsche Neuro-AIDS-Arbeitsgemeinschaft DNAA. Erkrankungen des peripheren Nervensystems und der Muskulatur bei der HIVInfektion. Nervenarzt., 2000, 71, 442-450.
14. Arendt, G.; Nolting, T.; Frisch, C.; Husstedt, I.W.; Gregor, N.; Kousilieri, E.; Maschke, M.; Angerer, A.; Obermann, M.; Neuen-Jacob, E.; Adams, O.; Loeffert, S.; Riederer, P.; ter Meulen, V.; Sopper, S. German competence network HIV/AIDS: Intrathecal viral replication and cerebral deficits in different stages of human immunodeficiency virus disease. J. NeuroVirol., 2007, 3, 225-232.
15. Arendt, G. Affective disorders in patients with HIV infection. CNS Drugs, 2006, 2, 507-518.
16. Boly, L.; Cafaro, V.; Dyne, R.T. Depressive symptoms predict increased incidence of neuropsychiatric side effects in patients treated with efavirenz. J. Acquir. Immune Defic. Syndr., 2006, 42, 514-515.
17. Harry, T.C.; Matthews, M.; Salvary, I. Indinavir use: associated reversible hair loss and mood disturbance. Int. J. STD AIDS, 2000, 11, 474-476.
18. Hawkins, T.; Geist, C.; Young, B.; Giblin, A.; Mercier, R.C.; Thornton, K.; Haubrich, R. Comparison of neuropsychiatric side effects in an observational cohort of efavirenz- and protease inhibitor-treated patients. HIV Clin. Trials, 2005, 6, 187-196.
19. Lafeuillade, A. Factors affecting adherence and convenience in antiretroviral therapy. Int. J. STD AIDS, 2001, 12, 18-24.
20. Perkins, D.; Evans, DL. HIV-related major depression: response to AZT treatment. Psychosomatics, 1991, 32, 451-458.
21. Antinori, A.; Arendt, G.; Becker, J.T.; Brew, B.J.; Byrd, D.A.; Cherner, M.; Clifford, D.B.; Cinque, P.; Epstein, L.G.; Goodkin, K.; Gisslen, M.; Grant, I.; Heaton, R.K.; Joseph, J.; Marder, K.; Marra, C.M.; McArthur, J.C.; Nunn, M.; Price, R.W.; Pulliam, L.; Robertson, K.R.; Sacktor, N.; Valcour, V.; Wojna, V.E. Updated research nosology for HIV-associated neurocognitive disorders. Neurology, 2000, 69, 1789-1799.
22. McArthur, J.; Brew, B.J.; Nath, A. Neurological complications of HIV infection. Lancet Neurol., 2005, 4, 543-555.
23. McArthur, J.C.; Haughey, N.; Gartner, S.; Conant, K.; Pardo, C.; Nath, A.; Sacktor, N. Human immunodeficiency virus-associated dementia: an evolving disease. J. NeuroVirol., 2003, 9, 205-221 .
24. Schweinsburg, B.C.; Taylor, M.J.; Alhassoon, O.M.; Gonzalez, R.; Brown, G.G.; Ellis, R.J.; Letendre, S.; Videen, J.S.; McCutchan, J.A.; Patterson, T.L.; Grant, I and the HNRC Group. Brain mitochondrial injury in human immunodeficiency virus-seropositive [HIV+] individuals taking nucleoside reverse transcriptase inhibitors. J. NeuroVirol., 2005, 11, 356-364.
25. K; Hudelmeier, B; Biehl, K; Reichelt, D et al. Abnahme der Kognition unter ddC, ddI und d4T als Komponente von HAART [Abstract]. Aktuelle Neurologie 2008, 35, 345
26. Cote, H.; Brumme, Z.L.; Craib, K.; Alexander, C.S.; Wynhoven, B.; Ting, L.; Wong, H.; Harris, M.; Harrigan, P.R.; O'Shaughnessy, M.V.; Montaner, J.S. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N. Engl. J. Med., 2002, 346, 811-820.
27. Dore, G.J.; Corell, P.K.; Li, Y.; Kaldor, J.M.; Cooper, D.A.; Brew, B.J. Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS, 1999, 13, 1249-1253.
28. Wang, J.; Chen, T.; Honma, M.; Chen, L.; Moore, M.M. 3'-azido-3'- deoxythymidine induces deletions in L5178Y mouse lymphomana cells. Environ. Mol. Mutagen., 2007, 48, 248-257.
29. Mc Mahon, D.K.; Dinubile, M.J.; Meibohm, A.R.; Marino, D.R.; Robertson, M.N. For the protokol 060 study group:efficacy, safety and tolerabilty of long-term combination antiretroviral therapy in asymptomatic treatment adults with early HIV-infection. HIV Clin. Trials, 2007, 8, 269-281.
30. Evers, S.; Wibbeke, B.; Reichelt, D.; Suhr, B., Brilla, R.; Husstedt, I. The impact of HIV infection on primary headache: unexpected findings from retrospective, cross-sectional, and prospective analyses. Pain, 2000, 85, 191-200.
31. Evers, S.; Husstedt, I.W. Kopfschmerzen während der HIVInfektion. Nervenarzt., 2008, 27, pp 833-888.
32. Portsmouth, S.; Imami, N.; Pires, A.; Stebbing, J.; Hand, J.; Nelson, M.; Gotch, F.; Gazzard, B.G. Treatment of primary HIV-1 infection with nonnucleoside reverse transcriptase inhibitor-based therapy is effective and well tolerated. HIV Med., 2004, 5, 26-29.
33. Happe, S.; Kundmüller, L.; Reichelt, D.; Husstedt, I.W.; Evers, S. Comorbidity of restless legs syndrome and HIV infection. J. Neurol., 2007, 10, 1401-146.
34. Dorey-Stein, Z.; Amorosa, V.K.; Kostman, J.R.; Lo Re, V 3rd; Shannon, R.P. Severe weight gain, lipodystrophy, dyslipidemia, and obstructive sleep apnea in a human immunodeficiency virusinfected patient following highly active antiretroviral therapy. J. Cardiometab. Syndr., 2008, 3, 111-114.
35. No authors listed. Depression is common among AIDS patients. Psych consult often is necessary. AIDS Alert, 2002, 17, 153-154.
36. von Einsiedel, R.W.; Berger, T.; Weisbrod, M.; Unverricht, S.; Hartmann, M. HIV-patients with psychiatric illness: treatment strategies and drug interactions. Nervenarzt., 2001, 72, 204-215.
37. Gutierrez, F.; Navarro, A.; Padilla, S.; Antón, R.; Masiá, M.; Borrás, J.; Martín-Hidalgo, A. Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. Clin. Infect. Dis., 2005, 41, 1648-1653 .
38. Cherry, C.L.; Skolasky, R.L.; Lal, L. Antiretroviral use and other risks for HIV-associated neuropathies in an international cohort. Neurology, 2005, 66, 867-873.
39. Pettersen, J.A.; Jones, G.; Worthington, C.; Krentz, H.B.; Keppler, O.T.; Hoke, A.; Gill, J.M.; Power, C. Sensory neuropathy in human immunodeficiency virus/acquired immunodeficiency syndrome patients: protease inhibitor-mediated neurotoxicity. Ann. Neurol., 2006, 59, 816-824.
40. Simpson, D; Estanislao, L; Evans, S; Verma, S; Micsa, E. HIVassociated neuromuscular weakness syndrome. AIDS, 2004, 18, 1403-1412.
41. Tagliati, M.; Grinnell, J.; Godbold, J.; Simpson, D.M. Peripheral nerve function in HIV infection: clinical, electrophysiologic, and laboratory findings. Arch. Neurol., 1999, 56, 84-89.
42. Wise, M.E.; Mistry, K.; Reid, S. Drug points: neuropsychiatric complications of nevirapine treatment. BMJ, 2002, 324, 879.
43. Lichtenstein, K.A.; Armon, C.; Baron, A.; Moorman, A.C.; Wood, K.C.; Holmberg, S.D. HIV outpatient study investigators: modification of the incidence of drug-associated symmetrical peripheral neuropathy by host and disease factors in the HIV outpatient study cohort. Clin. Infect. Dis., 2005, 40(1), 148-157.
44. Hulgan, T.; Haas, D.W.; Haines, J.L.; Ritchie, M.D.; Robbins, G.K.; Shafer, R.W.; Clifford, D.B.; Kallianpur, A.R.; Summar, M.; Canter, J.A. Mitochondrial haplogroups and peripheral neuropathy during antiretroviral therapy: an adult AIDS clinical trials group study. AIDS, 2005, 19(13), 1341-1349.
45. Sanjay, C.; Keswani, M.; Carlos, A.; Pardo, C.A; Catherine, L. Cherry, Ahmet Hoke and Justin C. McArthur HIV-associated sensory neuropathies. AIDS, 2002, 16, 2105-2117.
46. Esiri, M.M.; Morris, C.S.; Millard, P.R. Sensory and sympathetic ganglia in HIV-1 infection: immunocytochemical demonstration of HIV-1 viral antigens, increased MHC class II antigen expression and mild reactive inflammation. J. Neurol. Sci., 1993, 114, 178-187.
47. Griffin, J.W.; Wesselingh, S.L.; Griffin, D.E.; Glass, J.D.; McArthur, J.C.Peripheral nerve disorders in HIV infection. Similarities and contrasts with CNS disorders. Res. Publ. Assoc. Res. Nerv. Ment. Dis., 1994, 72, 159-182.
48. Bradley, W.G.; Shapshak, P.; Delgado, S.; Nagano, I.; Stewart, R.; Rocha, B.Morphometric analysis of the peripheral neuropathy of AIDS. Muscle Nerve, 1998, 21, 1188-1195.
49. Jones, G.; Zhu, Y.; Silva, C.; Tsutsui, S.; Pardo, C.A.; Keppler, O.T.; McArthur, J.C.; Power, C. Peripheral nerve-derived HIV-1 is predominantly CCR5-dependent and causes neuronal degeneration and neuroinflammation. Virology, 2005, 334, 178-193.
50. Gray, F; Chrétien, F; Vallat-Decouvelaere, AV; Scaravilli, F. The Changing Pattern of HIV Neuropathology in the HAART Era. J. Neuropathol. Exp. Neurol., 2003, 62, 429-440.
51. Benhammou, V.; Tardieu, M.; Warszawski, J.; Rustin, P.; Blanche, S.; Creighton, J.; Hauer, P.; Raman, S.P.; Moore, R.; Carter, K.; Thomas, D.; Ebenezer, G.J.; Wesselingh, S.L.; McArthur, J.C. Clinical mitochondrial dysfunction in uninfected children born to HIV-infected mothers following perinatal exposure to nucleoside analogues. Environ. Mol. Mutagen., 2007, 48, 173-178.
52. Hahn, K.; Arendt, G.; Braun, J.S.; von Giesen, H.J.; Husstedt, I.W.; Maschke, M.; Straube, M.E.; Schielke, E. German Neuro-AIDS Working Group. A placebo-controlled trial of gabapentin for painful HIV-associated sensory neuropathies. J. Neurol., 2004, 251, 1260-1266.
53. Authier, F.J.; Chariot, P.; Gherardi, R.K. Skeletal muscle involvement in human immunodeficiency virus [HIV]-infected patients in the era of highly active antiretroviral therapy [HAART]. Muscle Nerve, 2005, 32, 247-260.
54. Cupler, E.J.; Danon, M.J; Jay, C.; Ropka, M.; Dalakas, M.C. Early features of AZTe-associated myopathy: histopathological findings and clinical correlations. Acta Neuropathol., 1995, 90, 1-6.
55. Peters, B.S.; Winer, J.; Landon, D.N.; Stotter, A.; Pinching, A.J. Mitochondrial myopathy associated with chronic AZT therapy in AIDS. Quart. J. Med., 1993, 86, 5-15.
56. Simpson, D.M.; Kitch, D.; Evans, S.R.; McArthur, J.C.; Asmuth, D.M.; Cohen, B.; Goodkin, K.; Gerschenson, M.; So, Y.; Marra, C.M.; Diaz-Arrastia, R.; Shriver, S.; Millar, L.; Clifford, D.B. HIV neuropathy natural history cohort study: assessment measures and risk factors. Neurology, 2006, 66, 1679-1687.
57. Olivero, O.A.; Fernandez, J.J.; Antiochos, B.B.; Wagner, J.L.; Claire, S.; Poirier, M.E. Transplacental genotoxicity of combined antiretroviral nucleoside analogue therapy in Erythrocebus patas monkeys. J. Acquir. Immune Defic. Syndr., 2002, 29, 323-329.
58. Dominguez, K.; Bertolli, J.; Fowler, M.; Peters, V.; Ortiz, I.; Melville, S.; Rakusan, T.; Frederick, T.; Hsu, H.; D'Almada, P.; Maldonado, Y.; Wilfert, C. PSD Consortium. Perinatal Safety Review Working Group. Lack of definitive severe mitochondrial signs and symptoms among deceased HIV-uninfected and HIVindeterminate children < or 5 years of age, Pediatric Spectrum of HIV Disease project [PSD] USA. Ann. NY Acad. Sci., 2000, 918, 236-246.